Can I Take Vitamin D with Cytomel (Liothyronine)?
Liothyronine (brand name Cytomel) is a synthetic form of triiodothyronine (T3), a thyroid hormone, prescribed for hypothyroidism, often in combination with or instead of levothyroxine (synthetic T4). Vitamin D refers to two related compounds, cholecalciferol (D3) and ergocalciferol (D2), available as over-the-counter supplements or, for deficiency, prescription-strength doses. These are pharmacologically unrelated substances.
No published pharmacokinetic study has shown that vitamin D3 or D2, taken alone, reduces or increases absorption of liothyronine. The interaction that patients often read about, and that generates most of the online confusion, involves calcium, not vitamin D itself. Calcium carbonate and calcium citrate are well documented to bind thyroid hormone in the gut and reduce its absorption. Because many vitamin D tablets are co-formulated with calcium (for bone health combination products), the calcium effect gets attributed to the vitamin D. Plain cholecalciferol or ergocalciferol, without added calcium, does not carry that same absorption concern based on current pharmacological understanding. This distinction is the practical answer to the question most readers are actually asking.
This is general education, not a substitute for individualized advice from your prescriber or pharmacist, particularly if you take a combination supplement, have kidney disease, or take multiple thyroid or bone-related medications.
The direct answer
There is no established pharmacokinetic interaction between vitamin D (D2 or D3) and liothyronine. If your vitamin D product is calcium-free, taking it at the same time as liothyronine is unlikely to meaningfully change thyroid hormone absorption. If your product contains calcium, treat it the same way you would treat any calcium supplement around thyroid hormone dosing: separate it by several hours, consistent with standard thyroid hormone administration guidance for calcium and iron. Vitamin D deficiency is common in people with thyroid disease, and correcting it is a reasonable, separate goal from thyroid hormone dosing, monitored with its own labs.
Why the confusion exists: calcium, not vitamin D, is the known interactor
The interaction between calcium carbonate and levothyroxine is well established in the thyroid literature and is reflected in professional guidance for thyroid hormone administration: take thyroid hormone on an empty stomach and separate it from calcium and iron supplements by several hours. Liothyronine, like levothyroxine, is a thyroid hormone and would reasonably be expected to follow the same general administration caution around calcium, though liothyronine has faster absorption and a much shorter half-life (roughly a day, versus about a week for levothyroxine), so the clinical significance of a modest absorption delay may differ. This is an area where extrapolation from levothyroxine data to liothyronine is plausible but not separately proven in dedicated liothyronine studies, and that gap deserves to be stated plainly rather than assumed away.
Isolated vitamin D, without calcium, does not appear anywhere in the literature we could verify as an agent that binds or chelates thyroid hormone in the gut. Absorption of cholecalciferol occurs by passive diffusion and lipid-mediated pathways in the small intestine, a different route from the transporter-mediated absorption of thyroid hormone, which is one reason a direct pharmacokinetic clash is not mechanistically expected. That said, a plausible mechanism is not the same as a confirmed absence of interaction, and no dedicated liothyronine-vitamin D pharmacokinetic trial has been identified to close that gap definitively.
Vitamin D status and thyroid disease: a real association, not a dosing rule
Multiple observational studies have reported that people with hypothyroidism, and especially autoimmune (Hashimoto) thyroiditis, have lower average vitamin D levels than people without thyroid disease. The literature also includes reports that vitamin D repletion may modestly reduce thyroid antibody titers in some deficient patients over several months. These are genuine and clinically interesting findings, but the exact magnitude of any of these effects (prevalence percentages, antibody reduction percentages, fracture risk ratios) varies across studies and requires verification against the primary paper before being stated as a precise number in patient-facing material. We are deliberately not repeating specific percentages here because the citations available to us for those numbers could not be confirmed as attached to the correct paper.
What is reasonably well established, independent of thyroid status, is that adequate vitamin D supports intestinal calcium absorption and bone health, and that guideline bodies such as the Endocrine Society have published target ranges for 25-hydroxyvitamin D in deficient patients. Whether a hypothyroid or T3-treated patient needs a different target than the general population is a question for your prescriber, not a fixed rule.
The bone and calcium overlap is pharmacodynamic, not pharmacokinetic
The connection worth taking seriously is downstream, not at the absorption level. Excess thyroid hormone (from over-replacement rather than appropriate dosing) is associated with increased bone turnover and, in some observational cohorts, higher fracture risk. Vitamin D deficiency independently increases bone turnover through secondary hyperparathyroidism. If a patient has both a mildly elevated free T3 and low vitamin D at the same time, the two mechanisms could theoretically compound bone loss, even though neither substance interacts with the other's absorption.
Thyroid hormone receptor signaling has been studied at the level of mitochondrial and cellular metabolism, including work describing how thyroid hormone receptor isoforms influence mitochondrial activity (Casas et al., 2003). This kind of basic-science work explains why thyroid hormone has such broad effects on metabolic tissue, including bone, but it does not establish a specific vitamin D interaction and should not be read as clinical interaction evidence. It is background for why endocrinologists think about thyroid hormone status and skeletal health together, not a citation for a vitamin D dosing rule.
This means the practical takeaway is not "vitamin D and liothyronine interact," but "both affect bone and calcium metabolism through separate pathways, and if you are on long-term liothyronine, your prescriber has reason to track both your thyroid labs and your vitamin D and calcium status together."
Evidence-status interaction assessment
| Status | Claim | Basis | What to verify |
|---|---|---|---|
| Established | Vitamin D and liothyronine do not share known transporters or metabolic enzymes | Mechanistic pharmacology of each substance's absorption route | Not usually necessary to verify per patient |
| Established | Calcium (not vitamin D itself) reduces absorption of thyroid hormone when co-administered | Long-standing thyroid hormone administration guidance built around levothyroxine-calcium data | Confirm whether your vitamin D product contains added calcium (check the label) |
| Plausible, extrapolated | The calcium-separation caution that applies to levothyroxine likely applies similarly to liothyronine | Same drug class (thyroid hormone), no dedicated liothyronine-calcium trial identified | Ask your pharmacist whether liothyronine-specific data exists beyond levothyroxine extrapolation |
| Plausible, not confirmed by dedicated trial | No pharmacokinetic interaction exists between isolated cholecalciferol/ergocalciferol and liothyronine | Absence of published interaction reports; different absorption pathways | If your free T3 or TSH shifts unexpectedly after starting vitamin D, do not assume vitamin D is the cause without ruling out other factors |
| Real association, magnitude unverified | Hypothyroid and Hashimoto patients have higher rates of vitamin D insufficiency than the general population | Multiple observational studies, exact prevalence figures not independently confirmed here | Get your own 25(OH)D checked rather than relying on population averages |
| Not established | Vitamin D supplementation changes liothyronine dosing requirements | No trial evidence identified for this claim | Do not adjust your liothyronine dose based on vitamin D status without prescriber input |
| Not established | A specific percentage reduction in thyroid antibodies from vitamin D repletion applies broadly | Reported in some small trials on autoimmune thyroid disease; effect size not verified here as accurately cited | Ask your endocrinologist about antibody monitoring if you have Hashimoto's, rather than treating a repletion trial as a guarantee |
Practical timing
A reasonable, low-effort approach that avoids the calcium issue entirely:
- Take liothyronine on an empty stomach, consistent with standard thyroid hormone administration advice, at a consistent time each day.
- If your vitamin D product is calcium-free, take it whenever convenient, including with a meal that contains some fat, since vitamin D is fat-soluble and absorption may be improved with dietary fat present.
- If your vitamin D product contains calcium, or you also take a separate calcium supplement, separate it from liothyronine by several hours, the same way you would separate calcium from any thyroid hormone dose.
- If you take both levothyroxine and liothyronine, follow the calcium-separation window that applies to levothyroxine, since it is the more absorption-sensitive of the two.
Monitoring
Reasonable baseline and follow-up labs when vitamin D and liothyronine are used together include 25-hydroxyvitamin D, serum calcium, and thyroid function tests (free T3 and TSH, interpreted with the understanding that TSH is often suppressed intentionally on T3 therapy). Frequency and targets should be set by your prescriber based on your baseline levels and clinical picture; we are not providing individualized dosing or monitoring intervals here.
Contact your prescriber or seek urgent care if you develop symptoms suggestive of hypercalcemia (persistent nausea, unusual thirst, confusion, frequent urination) or thyroid hormone excess (resting heart rate persistently above 100, new tremor, unintentional weight loss, palpitations). These symptoms warrant evaluation regardless of which substance is the cause.
Special situations worth flagging to your prescriber
Kidney disease. Vitamin D activation is impaired in chronic kidney disease, and some patients require active vitamin D (calcitriol) rather than standard cholecalciferol. Calcitriol carries a higher hypercalcemia risk and needs closer monitoring, independent of thyroid hormone status.
Postmenopausal women and others at elevated fracture risk. Because both thyroid hormone excess and vitamin D deficiency affect bone, women who are postmenopausal and on long-term liothyronine may warrant a bone density discussion with their clinician. General population guidance on vitamin D and calcium supplementation for fracture prevention does not automatically apply to someone on thyroid hormone replacement, and this should be an individualized conversation.
Combination T4/T3 therapy. If you take both levothyroxine and liothyronine, the levothyroxine-calcium separation guidance should govern your supplement timing, since levothyroxine's absorption is more sensitive to interference.
What is not established
No trial to our knowledge has directly tested whether vitamin D changes liothyronine blood levels or clinical effect. No trial to our knowledge has tested whether liothyronine changes vitamin D metabolism. Claims about specific percentage improvements in antibody levels, fracture risk ratios, or absorption efficiency attributed to specific studies should be treated as unverified until checked against the original paper, and are intentionally left out of specific-number form on this page.
If you are already taking both without problems
If you have been taking vitamin D and liothyronine together and feel well, that is not, by itself, evidence of anything going wrong or right. Ask your prescriber to confirm that your most recent free T3, TSH, and 25(OH)D are in your individual target range. If they are, your current routine is reasonable. If a level is unexpectedly off, check your vitamin D product's label for added calcium before assuming vitamin D itself is the cause.
References
- Casas F, et al. Endocrine regulation of mitochondrial activity: involvement of truncated RXRalpha and c-Erb Aalpha1 proteins. 2003. https://pubmed.ncbi.nlm.nih.gov/12631582/
Other sources referenced in the prior version of this page could not be independently verified as matching the claims attached to them and have been removed pending confirmation. Specific prevalence figures, antibody reduction percentages, and fracture risk ratios mentioned in general terms above should be checked against the primary literature before being used in clinical decision-making.